Literature DB >> 15641051

Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells.

Nathalie Franchimont1, Cécile Lambert, Pascale Huynen, Clio Ribbens, Biserka Relic, Alain Chariot, Vincent Bours, Jacques Piette, Marie-Paule Merville, Michel Malaise.   

Abstract

OBJECTIVE: Interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R) activation of gp130 represents an alternative pathway for osteoclast development in inflammatory conditions. The goal of the present study was to investigate changes in sIL-6R levels in response to the inflammatory cytokines IL-1beta and tumor necrosis factor alpha (TNFalpha) and to determine the role of TNFalpha-converting enzyme (TACE) in this process.
METHODS: Levels of sIL-6R in the culture media of MG63 and SAOS-2 osteoblast-like cell lines after exposure to various agents were determined by immunoassay. TACE protein levels were measured by Western immunoblotting. Cells were transfected with small interfering RNA (siRNA) or with an expression plasmid for IL-6R and TACE to determine the potential involvement of TACE in IL-6R shedding.
RESULTS: IL-1beta and TNFalpha increased the levels of sIL-6R in the culture media of MG63 osteoblast-like cells. This effect was not influenced by cycloheximide or 5,6-dichlorobenzimidazole riboside but was markedly inhibited by the calcium chelator EGTA and by the TACE and matrix metalloproteinase inhibitor hydroxamate (Ru36156). IL-1beta and TNFalpha had no influence on the alternatively spliced form of IL-6R RNA. Levels of sIL-6R were reduced when MG63 cells were transiently transfected with TACE siRNA. Transfection of SAOS-2 cells with expression plasmids for IL-6R and TACE produced a dose-dependent increase in sIL-6R levels.
CONCLUSION: IL-1beta- and TNFalpha-mediated induction of IL-6R shedding in osteoblast-like cells is at least partly dependent on TACE activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15641051     DOI: 10.1002/art.20727

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  13 in total

Review 1.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

2.  Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.

Authors:  Héctor F Araya; Hugo Sepulveda; Carlos O Lizama; Oscar A Vega; Sofia Jerez; Pedro F Briceño; Roman Thaler; Scott M Riester; Marcelo Antonelli; Flavio Salazar-Onfray; Juan Pablo Rodríguez; Ricardo D Moreno; Martin Montecino; Martine Charbonneau; Claire M Dubois; Gary S Stein; Andre J van Wijnen; Mario A Galindo
Journal:  J Cell Biochem       Date:  2018-06-19       Impact factor: 4.429

3.  The role of the hypothalamic-pituitary-adrenal axis in modulating seasonal changes in immunity.

Authors:  Kamau Pierre; Naomi Schlesinger; Ioannis P Androulakis
Journal:  Physiol Genomics       Date:  2016-06-24       Impact factor: 3.107

Review 4.  Tumor necrosis factor-alpha converting enzyme: Implications for ocular inflammatory diseases.

Authors:  Kota V Ramana
Journal:  Int J Biochem Cell Biol       Date:  2010-03-18       Impact factor: 5.085

5.  Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Authors:  Christian Hundhausen; Alena Roth; Elizabeth Whalen; Janice Chen; Anya Schneider; S Alice Long; Shan Wei; Rebecca Rawlings; MacKenzie Kinsman; Stephen P Evanko; Thomas N Wight; Carla J Greenbaum; Karen Cerosaletti; Jane H Buckner
Journal:  Sci Transl Med       Date:  2016-09-14       Impact factor: 17.956

6.  Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis.

Authors:  Thanh-Thuy T Le; Harry Karmouty-Quintana; Ernestina Melicoff; Thanh-Truc T Le; Tingting Weng; Ning-Yuan Chen; Mesias Pedroza; Yang Zhou; Jonathan Davies; Kemly Philip; Jose Molina; Fayong Luo; Anuh T George; Luis J Garcia-Morales; Raquel R Bunge; Brian A Bruckner; Matthias Loebe; Harish Seethamraju; Sandeep K Agarwal; Michael R Blackburn
Journal:  J Immunol       Date:  2014-08-29       Impact factor: 5.422

7.  The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6.

Authors:  LaShon C Sturgis; Joseph G Cannon; Derek A Schreihofer; Michael W Brands
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-10-07       Impact factor: 3.619

8.  Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.

Authors:  Yu Zheng; Dennis Basel; Shu-Oi Chow; Colette Fong-Yee; Sarah Kim; Frank Buttgereit; Colin R Dunstan; Hong Zhou; Markus J Seibel
Journal:  Clin Exp Metastasis       Date:  2014-09-16       Impact factor: 5.150

9.  Effect of TNF-α and IL-6 on Compact Bone-Derived Cells.

Authors:  Yiming Zhang; Xianqi Li; Takahiro Chihara; Hongwei Dong; Hideaki Kagami
Journal:  Tissue Eng Regen Med       Date:  2021-04-13       Impact factor: 4.169

Review 10.  Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation.

Authors:  Juliane Lokau; Maria Agthe; Christoph Garbers
Journal:  Mediators Inflamm       Date:  2016-07-14       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.